

References

- Adorini, L.; Harvey, M. A.; Miller, A.; Sercarz, E. E. 1979. Fine specificity of regulatory T-cells. *Journal of Experimental Medicine* **150**: 293-306.
- Amara, R. R.; Villinger, F.; Altman, J. D.; Lydy, S. L.; O'Neil, S. P.; Staprans, S. I.; Montefiori, D. C.; Xu, Y.; Herndon, J. G.; Wyatt, L. S.; Candido, M. A.; Kozyr, N. L.; Earl, P. L.; Smith, J. M.; Ma, H.; Grimm, B. D.; Hulsey, M. L.; Miller, J.; McClure, H. M.; McNicholl, J. M.; Moss, B.; Robinson, H. L. 2001. Control of mucosal challenge and prevention of AIDS by a multiprotein DNA/ MVA vaccine. *Science* **292**: 69-75.
- André, F. E. 1995. Approaches to a vaccine against Hepatitis A: development and manufacture of an inactivated vaccine. *The Journal of Infectious Diseases* **171** S33-S39.
- Appel, M. 1978. Reversion to virulence of attenuated distemper virus *in vivo* and *in vitro*. *Journal of General Virology* **41**: 385-393.
- Bahnemann, H. G. 1990. Inactivation of viral antigens for vaccines preparation with particular reference to the application of binary ethylenimine. *Vaccine* **8**: 299-303.
- Basak, A. K.; Gouet, P.; Grimes, J.; Roy, P.; Stuart, D. 1996. Crystal structure of the top domain of African horse sickness virus VP7: comparison with Bluetongue virus VP7. *Journal of Virology* **70**: 3797-3806.
- Bentley, L.; Fehrsen, J.; Jordaan, F.; Huismans, H.; du Plessis, D. H. 2000. Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries. *Journal of General Virology* **81**: 993-1000.
- Ben-Yedidya, T.; Arnon, R. 1997. Design of peptide and polypeptide vaccines. *Current Opinion in Biotechnology* **8**: 442-448.
- Beterams, G.; Böttcher, B.; Nassal, M. 2000. Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. *FEBS Letters* **481**: 169-76.
- Better, M.; Chang, C. P.; Robinson, R. R.; Horwitz, A. H. 1988. *Escherichia coli* secretion of an active chimeric antibody fragment. *Science* **240**: 1041-1043.
- Birnboim, H. C.; Dolly, J. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acid Research* **7**: 1513-1523.
- Boleti, E.; Deonarain, M. P.; Spooner, R. A.; Smith, A. J.; Epenetos, A. A.; George, A. J. 1995. Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein. *Annals of Oncology* **6**: 945-947.
- Borden, E. C.; Shope, R. E.; Murphy, F. A. 1971. Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus—a new taxonomic group. Physicochemical and serological studies. *Journal of General Virology* **13**: 261-271.

Boulian, G. L.; Hozumi, N.; Shulman, M. J. 1984. Production of functional chimeric mouse/human antibody. *Nature* 312: 643-646.

Brochier, B.; Boulanger, D.; Costy, F.; Pastoret, P. 1994. Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. *Vaccine* 12: 1363-1488.

Brown, F. 1993. Review of accidents caused by incomplete inactivation of viruses. *Developments in biological standardization* 81: 103-107.

Burnette, W. N. 1991. Recombinant subunit vaccines. *Current Opinion in Biotechnology* 2: 882-892.

Burroughs, J. N.; O'Hara, R. S.; Smale, C. J.; Hamblin, C.; Walton, A.; Armstrong, R.; Mertens, P. P. C. 1994. Purification and properties of virus particles, infectious subviral particles, cores and VP7 crystals of African horsesickness virus serotype 9. *Journal of General Virology* 75: 1849-1857.

Cabezas, E.; Wang, M.; Parren, P. W. H. I.; Stanfield, R. L.; Satterthwait, A. C. 2000. A Structure-Based Approach to a Synthetic Vaccine for HIV-1. *Biochemistry* 39: 14377-14391.

Chuma, T.; Le Blois, H.; Sánchez-Vizcaíno, J. M.; Diaz-Laviada, M.; Roy, P. 1992. Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-diagnostic reagent. *Journal of General Virology* 73: 925-931.

Chung, T.; Miller, R. H. 1988. A rapid and convenient method for the preparation and storage of competent cells. *Nucleic Acid Research* 16: 3580.

Coëffier, E.; Clement, J. M.; Cussac, V.; Khodaei-Boorane, N.; Jehanno, M.; Rojas, M.; Dridi, A.; Latour, M.; El Habib, R.; Barre-Sinoussi, F.; Hofnung, M.; Leclerc, C. 2001. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. *Vaccine* 19: 684-693.

Cohen, S. N.; Chang, A. C.; Hsu, L. 1972. Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. . *Proceedings of the National Academy of Science of the United States of America* 69: 2110-2114.

Conry, R. M.; LoBuglia, A. F.; Wright, M.; Sumerel, L.; Pike, M. J.; Johanning, F.; Benjamin, R.; Lu, D.; Curiel, D. T. 1995. Characterization of a messenger RNA polynucleotide vaccine vector. *Cancer research* 55: 1397-1400.

Dalsgaard, K.; Uttenthal, A.; Jones, T. D.; Xu, F.; Merryweather, A.; Hamilton, W. D. O.; Langeveld, J. P. M.; Boshuizen, R. S.; Kamstrup, S.; Lomonossoff, G. P.; Porta, C.; Vela, C.; Casal, J. I.; Meloen, R. H.; Rodgers, P. B. 1997 Plant-derived vaccine protects target animals against a viral disease Nature Biotechnology Volume 15 Number 3 p248

Dalgleish, A. G.; Kennedy, R. C. 1988. Anti-idiotypic antibodies as immunogens: idiotype-based vaccines. *Vaccine* 6: 215-220.

Davis, H. L.; Weeranta, R.; Waldschmidt, T. J.; Tygrett, L.; Schorr, J.; Krieg A. M. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen 1. *Journal of Immunology* 160: 870-876.

de Jonga, J. C.; van Nieuwstadt, A. P.; Kimman, T. G.; Loeffen, W. L. A.; Bestebroer, T. M.; Bijlsma, K.; Verweij, C.; Osterhaus, A. D. M. E.; Claas, E. C. J. 1999. Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. *Vaccine* 17: 1321-1328.

Deneer, H. G.; Potter, A. A. 1989. Effect of iron restriction on the outer membrane proteins of *Actinobacillus (Haemophilus) pleuropneumoniae*. *Infection and Immunity* 57: 798-804.

Dertzbaugh, M. T. 1998. Genetically engineered vaccines: an overview. *Plasmid* 39: 100-113.

Donnelly, J. J.; Ulmer, J. B.; Shiver, J. W.; Liu, M. A. 1997. DNA Vaccines. *Annual Reviews in Immunology* 15: 617-648.

Donnenberg, M. S.; Kaper, J. B. 1991 Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. *Infection and immunity*, 59: P 4310-4317

Duque, H.; Marshall, R. L.; Israel, B. A.; Letchworth, G. J. 1989. Effects of formalin inactivation on bovine herpes virus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits. *Vaccine* 7: 513-520.

Ellis, R. W. 2001. Technologies for the design, discovery, formulation and administration of vaccines. *Vaccine* 19: 2681-2687.

Ertl, H. C. J.; Xiang, Z. 1996. Novel vaccine approaches. *The Journal of Immunology* 156: 3579-3582.

Farrell, H. E.; McLean, C. S.; Harley, C.; Efsthathiou, S.; Inglis, S.; Minson A.C. 1994. Vaccine potential of a Herpes Simplex virus type 1 mutant with an essential glycoprotein deleted. *Journal of Virology* 68: 927-932.

Fischetti, V. A.; Medaglini, D.; Pozzi, G. 1996. Gram-positive commensal bacteria for mucosal vaccine delivery. *Current Opinion in Biotechnology* 7: 659-666.

Ferguson, M., Wood, D. J.; Minor, P.D. 1993. Antigenic structure of poliovirus in inactivated vaccines. *Journal of General Virology* 74: 685-690.

Fries, L. F.; Tartaglia, J.; Taylor, J.; Kauffman, E. K.; Meignier, B.; Paoletti, E.; Plotkin, S. 1996. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. *Vaccine* 14: 428-434.

Fukusho, A.; Ritter, G. D.; Roy, P. 1987. Variation in the bluetongue virus neutralization protein VP2. *Journal of General Virology* 68: 2967-2973.

Fynan, E. F.; Webster, R. G.; Fuller, D. H.; Haynes, J. R.; Santoro, J. C.; Robinson H. L. 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. *Proceedings of the National Academy of Science of the United States of America* 90: 11478-11482.

George, A. J. T.; Jamar, F.; Tai, M.; Heelan, B. T.; Adams, G. P.; McCartney, J. E.; Houston, L. L.; Weiner, L. M.;

Oepermann, H.; Peters, A. M.; Huston, J. S. 1995. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. *Proceedings of the National Academy of Science of the United States of America* 92: 8358-8362.

Georgiou, G.; Poetschke, H. L.; Stathopoulos, C.; Francisco, J. A. 1993. Practical applications of engineering gram-negative bacterial cell surfaces. *Trends in Biotechnology* 11: 6-10.

Geourjon, C.; Deleage, G.; Roux, B. 1991. ANTHEPROT: An interactive graphics software for analysing protein structures from sequences. *Journal of Molecular Graphics* 9: 188-190.

Geourjon, C.; Deleage, G. 1995. ANTHEPROT 2.0: A three-dimensional module fully coupled with protein sequence analysis methods. *Journal of Molecular Graphics* 13: 209-212.

Ghosh, M. K.; Dériaud, E.; Saron, M.; Lo-Man, R.; Henry, T.; Jiao, X.; Roy, P.; Leclerc, C. 2002. Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. *Vaccine* 20: 1369-1377.

Grimes, J.; Basak, A. K.; Roy, P.; Stuart, D. 1995. The crystal structure of bluetongue virus VP7. *Nature* 373: 167-170.

Hiatt, A.; Cafferkey, R.; Bowdish, K. 1989. Production of antibodies in transgenic plants. *Nature* 342: 76-78.

Hilleman, M. R. 2000. Overview of vaccinology with special reference to papillomavirus vaccines. *Journal of Clinical Virology* 19: 79-90.

Hopp, T. P.; Woods, K. R. 1981. Prediction of protein antigenic determinants from amino acid sequences. *Proceedings of the National Academy of Science of the United States of America* 78: 3824-3828.

Hopp, T. P.; Woods, K. R. 1983. A computer program for predicting protein antigenic determinants. *Molecular Immunology* 20: 483-489.

Hsu, S.; Schadeck, E. B.; Delmas, A.; Shaw, M.; Steward, M. W. 1996. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. *Vaccine* 14: 1159-1166.

Huismans, H.; van der Walt, N. T.; Cloete, M.; Erasmus, B. J. 1987. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. *Virology* 157: 172-179.

Huston, J. S.; McCartney, J.; Tai, M.; Mottola-Hartshorn, C.; Jin, D.; Warren, F.; Keck, P.; Oppermann, H. 1993. Medical application of single-chain antibodies. *International Reviews of Immunology* 10: 195-217.

Huter, V.; Hensel, A.; Brand, E.; Lubitz, W. 2000. Improved protection against lung colonization by *Actinobacillus pleuropneumoniae* ghosts: characterization of a genetically inactivated vaccine. *Journal of Biotechnology* 83: 161-172.

Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. 2000. Preparation and properties of totally synthetic immunogens. *Vaccine* 18: 355-361.

Jemmerson, R. 1987. Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies. *Proceedings of the National Academy of Science of the United States of America* 84: 9180-9184.

Kaumaya, P. T. P.; VanBuskirk, A. M.; Goldberg, E.; Pierce, S. K. 1992. Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C₄) as vaccines. *The Journal of Biological Chemistry* 267: 6338-6346.

Kim, J. J.; Ayyavoo, V.; Bagarazzi, M. L.; Chattergoon, M. A.; Dang, K.; Wang, B.; Boyer, J. D.; Weiner, D. B. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. *Journal of Immunology* 158: 816-826.

Kit, S.; Sheppard, M.; Ichimura, H.; Kit, M. 1987. Second generation pseudorabies virus vaccine with deletions in the thymidine kinase and glycoprotein genes. *American Journal of Veterinary Research* 48: 780-793.

Kowalski, J.; Gilbert, S. A.; van Drunen-Little-van den Hurk, S.; van den Hurk, J.; Babiuk, L. A.; Zamb, T. J. 1993. Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoprotein in transfected cells. *Vaccine* 11: 1100-1108.

Krieg, A. M.; Yi, A.; Matson, S.; Waldschmidt, T. J.; Bishop, G. A.; Teasdale, R.; Koretzky; Klinman, D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374: 546-549.

Kuhn, R. J.; Niesters, H. G. M.; Hong, Z.; Strauss, J. H. 1991. Infectious RNA transcripts from Ross River virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus. *Virology* 182: 430-441.

Kuhn, R. J.; Griffin, D. E.; Zhang, H.; Niesters, H. G. M.; Strauss, J. H. 1992. Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA. *Journal of Virology* 66: 7121-7127

Kuklin, N.; Daheshia, M.; Karem, K.; Manickan, E.; Rouse, B. T. 1997. Induction of mucosal immunity against Herpes Simplex virus by plasmid DNA immunization. *Journal of Virology* 71: 3138-3145.

Kunkel, M.; Lorinczi, M.; Rijnbrand, R.; Lemon, S. M.; Watowich, S. J. 2001. Self-assembly of nucleocapsid-like particles from recombinant Hepatitis C virus core protein. *Journal of Virology* 75: 2119-2129.

Kurilla, M. G.; Swaminathan, S.; Welsh, R. M.; Kieff, E.; Brutkiewicz, R. R. 1993. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. *Journal of Virology* 67: 7623-7628.

Kwissa, M.; Kroger, A.; Hauser, H.; Reimann, J.; Schirmbeck, R. 2003. Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. *Journal Molecular Medicine* 81: 91-101

Laden, J.; Philibert, P.; Torreilles, F.; Pugnière, M.; Martineau, P. 2002. Expression and folding of an antibody fragment selected *in vivo* for high expression levels in *Escherichia coli* cytoplasm. *Research in Microbiology* 153: 469-474.

Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 15: 680-685.

Le Blois, H.; Roy, P. 1993. A single point mutation in the VP7 major core protein of bluetongue virus prevents the formation of core-like particles. *Journal of Virology* 67: 353-359.

LeClaire, R. D.; Hunt, R. E.; Bavari, S. 2002. Protection against bacterial superantigen Staphylococcal enterotoxin B by passive vaccination. *Infection and Immunity* **70**: 2278–2281.

Levine, M. M.; Kaper, J. B.; Black, R. E.; Clements, M. L. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. *Microbiological Reviews* **47**: 510-550.

Levine, M. M.; Ferreccio, C.; Black, R. E.; Germanier, R. 1987. Large scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formation. *The Lancet* **2**: 1049-1052.

Lewis, P. J.; van Drunen Littel-van den Hurk, S.; Babiuk, L. A. 1999. Induction of immune responses to bovine herpesvirus type 1 gD in passively immune mice after immunization with a DNA-based vaccine. *Journal of General Virology* **80**: 2829–2837.

Liang, X.; Chow, B.; Babiuk, L. A. 1997. Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cattle. *Vaccine* **15**: 1057-1064.

Liljeqvist, S.; Ståhl, S. 1999. Production of recombinant subunit vaccines: protein immunogens, live delivery and nucleic acid vaccines. *Journal of Biotechnology* **73**: 1-33.

Limn, C. K.; Stauber, N.; Monastyrskaya, K.; Gouet, P.; Roy, P. 2000. Functional dissection of the major structural protein of bluetongue virus: identification of key residues within VP7 essential for capsid assembly. *Journal of Virology* **74**: 8658-69.

Little, M.; Kipriyanov, S. M.; Le Gall, F.; Moldenhauer, G. 2000. Of mice and men: hybridoma and recombinant antibodies. *Immunology Today* **21**: 364-370.

Löwenadler, B.; Lycke, N. 1994. Fusion proteins with heterologous T helper epitopes. Recombinant *E. coli* heat-stable enterotoxin proteins. *International Reviews of Immunology* **11**: 103-111.

Maree, S.; Durbach, S.; Huismans, H. 1998. Intracellular production of African horse sickness virus core-like particles by expression of the two major core proteins, VP3 and VP7, in insect cells. *Journal of General Virology* **79**: 333-337.

Maree, F. F. 2000. Multimeric protein structures of African horse sickness virus and their use as antigenic delivery systems. *Thesis submitted in the fulfillment of the requirements for the Degree Philosophy Doctorales (University of Pretoria)*.

Martínez-Torrecuadrada, J. L.; Langeveld, J. P. M.; Meloen, R. H.; Casal, J. I. 2001. Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides. *Journal of General Virology* **82**: 2415-2424.

Martinon, F.; Krishnan, S.; Lenzen, G.; Magné, R.; Gomard, E.; Guillet, J.; Lévy, J.; Meulien P. 1993. Induction of virus-specific cytotoxic T lymphocytes *in vivo* by liposome-entrapped mRNA. *European Journal of Immunology* **23**: 1719-1722.

Medina, E.; Guzmán, C. A. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. *Vaccine* **19**: 1573-1580.

Melamed, D.; Leitner, G.; Heller, E. D. 1991. A vaccine against avian colibacillosis based on ultrasonic inactivation of *Escherichia coli*. *Avian Diseases* 35: 17-22.

Mertens, P. P. C.; Burroughs, J. N.; Walton, A.; Wellby, M. P.; Fu, H.; O'Hara, R. S.; Brookes, S. M.; Mellor, P. S. 1996. Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two *Culicoides* vector species. *Virology* 217: 582-593.

Meyer, Q. C. 2002. The presentation of an HIV-1 neutralizing epitope on the surface of major structural protein VP7 of African horse sickness virus. *Thesis submitted in the fulfillment of the requirements for the Degree MSc (University of Pretoria)*.

Minor, P. D.; John, A.; Ferguson, M.; Icenogle, J. P. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion of a primary vaccine. *Journal of General Virology* 67: 693-706.

Monastyrskaya, K.; Gould, E. A.; Roy, P. 1995. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein. *Journal of Virology* 69:2831-41.

Monastyrskaya, K.; Staeuber, N.; Sutton, G.; Roy, P. 1997. Effects of domain-switching and site-directed mutagenesis on the properties and functions of the VP7 proteins of two Orbiviruses. *Virology* 237: 217-227.

Nelson, C. A.; Roof, R. W.; McCourt, D. W.; Unanue E. R. 1992. Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-A^k. *Proceedings of the National Academy of Science of the United States of America* 89: 7380-7383.

Netter, H. J.; Macnaughton, T. B.; Woo, W.; Tindle, R.; Gowans, E. J. 2001. Antigenicity and immunogenicity of novel chimeric Hepatitis B surface antigen particles with exposed Hepatitis C virus epitopes. *Journal of Virology* 75: 2130-2141.

Nilsson, J.; Ståhl, S.; Lundeberg, J.; Uhlén, M.; Nygren, P. 1997. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. *Protein Expression and Purification* 11: 1-16.

Nutall, P. A.; Jacobs, S. C.; Jones, L. D.; Carey, D.; Moss, S. R. 1992. Enhanced neurovirulence of tick-borne *Orbivirus* resulting from genetic modulation. *Virology* 187: 407-412.

Nygren, P.; Ståhl, S.; Uhlén, M. 1994. Engineering proteins to facilitate bioprocessing. *Trends in Biotechnology* 12: 184-188.

Ohno, K.; Sawai, K.; Iijima, Y.; Levin, B.; Meruelo, D. 1997 Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A
Nature Biotechnology August Volume 15 Number 8 p763

Oldfield, S.; Adachi, A.; Urakawa, T.; Hirasawa, T.; Roy, P. 1990. Purification and characterization of the major group-specific core antigen VP7 of bluetongue virus synthesized by a recombinant baculovirus. *Journal of General Virology* 71: 2649-2656.

Poskitt, D. C.; Jean-Francois, M. J. B.; Turnbull, S.; Macdonald, L.; Yasmeen, D. 1991. Internal image (Ab₂β) anti-idiotype vaccines. Theoretical and practical aspects. *Vaccine* **9**: 792-796.

Pushko, P.; Parker, M.; Ludwig, G. V.; Davis, N. L.; Johnston, R. E.; Smith, J. F. 1997. Replicon-helper systems from attenuated Venezuelan Equine Encephalitis virus: expression of heterologous genes *in vitro* and immunization against heterologous pathogens *in vivo*. *Virology* **239**: 389-401.

Rauly, I.; Goetsch, L.; Haeuw, J.; Tardieu, C.; Baussant, T.; Bonnefoy, J.; Corvaia, N. 1999. Carrier properties of a protein derived from outer membrane protein A of *Klebsiella pneumoniae*. *Infection and Immunity* **67**: 5547-5551

Reddy, P. S.; Idamakanti, N.; Chen, Y.; Whale, T.; Babiuk, L. A.; Mehtali, M.; Tikoo, S. K. 1999. Replication-defective bovine Adenovirus type 3 as an expression vector. *Journal of Virology* **73**: 9137-9144.

Rennels, M. B.; Glass, R. I.; Dennehy, P. H.; Bernstein, D. I.; Pichichero, M. E.; Zito, E. T.; Mack, M. E.; Davidson, B. L.; Kapikian A. Z. 1996. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. *Pediatrics* **97**: 7-13.

Riley, J. E. 2003. Construction of a new peptide insertion site in the top domain of major core protein VP7 of African horsesickness virus. *Thesis submitted in the fulfillment of the requirements for the Degree MSc (University of Pretoria)*.

Romito, M.; Du Plessis, D. H.; Viljoen, G. J. 1999. Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. *Onderstepoort Journal of Veterinary Research* **66**: 139-44.

Roy, P.; Hirasawa, T.; Fernandez, M.; Blinov, V. M.; Sanchez-Vixcain Rodrique, J. M. 1991. The complete sequence of the group-specific antigen, VP7, of African horsesickness disease virus serotype 4 reveals a close relationship to bluetongue virus. *Journal of General Virology* **72**: 1237-1241.

Roy, P.; Mertens, P. P. C.; Casal, I. 1994. African horse sickness virus structure. *Comparative Immunology, Microbiology and Infectious Diseases* **17**: 243-273.

Roy, P. 1996. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. *Intervirology* **39**: 62-71.

Roy, P.; Bishop, D. H.; Howard, S.; Aitchison, H.; Erasmus, B. 1996. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. *Journal of General Virology* **77**: 2053-2057.

Ruprecht, R. M. 1999. Live attenuated AIDS viruses as vaccines: promise or peril? *Immunological Reviews* **170**: 135-149.

Sambhi, S. K.; Kohonen-Corish, M. R. J.; Ramshaw, I. A. 1991. Local production of tumor necrosis factor encoded by recombinant Vaccinia virus is effective in controlling viral replication *in vivo*. *Proceedings of the National Academy of Science of the United States of America* **88**: 4025-4029.

Sambrook, J.; Fritsch, F. F.; Maniatis, T. 1989. Molecular Cloning: Laboratory Manual. Second Edition. *Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA*.

Scanlen, M.; Paweska, J. T.; Verschoor, J. A.; van Dijk, A. A. 2002. The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. *Vaccine* 20: 1079-1088.

Schultz-Cherry, S.; Dybing, J. K.; Davis, N. L.; Williamson, C.; Suarez, D. L.; Johnston, R.; Perdue, M. L. 2000. Influenza virus (A/HK/156/97) hemagglutinin expressed by an Alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. *Virology* 278: 55-59.

Shearer, G. M.; Clerici, M. 1997. Vaccines strategies: selective elicitation of cellular or humoral immunity? *Trends in Biotechnology* 15: 106-109.

Shewan, P. E.; Wilkie, B. N. 1982. Cytotoxin of *Pasteurella haemolytica* acting on bovine leukocytes. *Infection and Immunity* 35: 91-94.

Simard, C.; Nadon, F.; Séguin, C.; Thien, N. N.; Binz, H.; Basso, J.; Laliberté, J.; Trudel, M. 1997. Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 from the G glycoprotein: the role of cysteinyl residues in protection. *Vaccine* 15: 423-432.

Somogyi, P.; Frazier, J.; Skinner, M. A. 1993. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. *Virology* 197: 439-444.

Ståhl, S.; Uhlén, M. 1997. Bacterial surface display: trends and progress. *Trends in Biotechnology* 15: 185-192.

Stone-Marschat, M. A.; Moss, S. R.; Burrage, T. G.; Barber, M. L.; Roy, P.; Laegreid, W. W. 1996. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. *Virology* 220: 219-222.

Stoger, E.; Sack, M.; Fischer, R.; Christou, P. 2002. Plantibodies: applications, advantages and bottlenecks. *Current Opinion in Biotechnology* 13: 161-166.

Tam, J. P. 1996. Recent advances in multiple antigen peptides. *Journal of Immunological Methods* 196: 17-32.

Taylor, M. B.; Van Der Meyden, C. H.; Erasmus, B. J.; Reid, R.; Labuschagne, J. H.; Dreyer, L.; Prozesky, O. W. 1992. Encephalitis and chorioretinitis associated with neurotrophic African horse sickness virus infection in laboratory workers. IV. Experimental infection of the vervet monkey *Cercopithecus pygerythrus*. *South African Medical Journal* 81: 462-467.

Thornton, D. H. 1986. A survey of mycoplasma detection in veterinary vaccines. *Vaccine* 4: 237-240.

Treanora, J. J.; Kotloff, K.; Betts, R. F.; Belshe, R.; Newman, F.; Iacuzio, D.; Witter, J.; Bryant M. 2000. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. *Vaccine* 18: 899-906

Tubulekas, I.; Berglund, P.; Fleeton, M.; Liljeström, P. 1997. Alphavirus expression vectors and their use as recombinant vaccines: a mini review. *Gene* 190: 191-195.

Uhlén, M.; Forsberg, G.; Moks, T.; Hartmanis, M.; Nilsson, B. 1992. Fusion proteins in biotechnology. *Current Opinion in Biotechnology* 3: 363-369.

Ulmer, J. B.; Deck, R. R.; Dewitt, C. M.; Donnelly, J. J.; Liu, M. A. 1996. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. *Immunology* 89: 59-67.

Valenzuela, P.; Medina, A.; Rutter, W. J.; Ammerer, G.; Hall, B. D. 1982. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. *Nature* 298:347-50.

Van Regenmortel, M. H. V. 2001. Antigenicity and immunogenicity of synthetic peptides. *Biologicals* 29: 209-213.

Van Staden, V.; Huismans, H. 1991. A comparison of the genes which encode non-structural protein NS3 of different orbiviruses. *Journal of General Virology* 72: 1073-1079.

Vaughn, D. W.; Hoke Jr, C. H.; Yoksan, S.; LaChance, R.; Innis, B. L.; Rice, R. M.; Bhamarapravati, N. 1996. Testing of a Dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. *Vaccine* 14: 329-336.

Venter, M.; Napier, G.; Huismans, H. 2000. Cloning, sequencing and expression of the gene that encodes the major neutralisation-specific antigen of African horsesickness virus serotype 9. *Journal of Virological Methods* 86: 41-53.

Verma, R.; Boleti, E.; George A. J. T. 1998. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. *Journal of Immunological Methods* 216: 165-181.

Vinner, L.; Nielsen, H. V.; Bryder, K.; Corbet, S.; Nielsen, C.; Fomsgaard, A. 1999. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. *Vaccine* 17: 2166-2175.

Vogel, M.; Cichutek, K.; Norley, S.; Kurth, R. 1993. Self-limiting infection by *int/nef*-double mutants of Simian Immunodeficiency virus. *Virology* 193: 115-123.

Vreede, F. T.; Huismans, H. 1994. Cloning, characterization and expression of the gene that encodes the major neutralization-specific antigen of African horsesickness virus serotype 3. *Journal of General Virology* 75: 3629-3633.

Wade-Evans, A. M.; Pullen, L.; Hamblin, C.; O'Hara, R.; Burroughs, J. N.; Mertens, P. P. C. 1997. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. *Journal of General Virology* 78: 1611-1616.

Wade-Evans, A. M.; Pullen, L.; Hamblin, C.; O'Hara, R.; Burroughs, J. N.; Mertens, P. P. C. 1998. VP7 from African horse sickness virus serotype 9 protects mice against a lethal, heterologous serotype challenge. *Archives of Virology* 14: 211-219.

Wareing, M. D.; Tannock G. A. 2001. Live attenuated vaccines against influenza; an historical review. *Vaccine* 19: 3320-3330.

Wensvoort, G.; Terpstra, C. 1988. Bovine viral diarrhoea virus infections in piglets born to sows vaccinated against swine fever with contaminated vaccine. *Research in veterinary science* 45:143-148.

Wolff, J. A.; Malone, R. W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P. L. 1990. Direct gene transfer into mouse muscle *in vivo*. *Science* 247: 1465-1468.

Xiong, S.; Gerloni, M.; Zanetti, M. 1997. *In vivo* role of B lymphocytes in somatic transgene immunization. *Proceedings of the National Academy of Science of the United States of America* 94: 6352-6357.

Yankauckas, M. A.; Morrow, J. E.; Parker, S. E.; Abai, A.; Rhodes, G. H.; Dwarki, V. J.; Gromkowski, S. H. 1993. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. *DNA and Cell Biology* 12: 771-776.

Yilma, T.; Hsu, D.; Jones, L.; Owens, S.; Grubman, M.; Mebus, C.; Yamanaka, M.; Dale, B. 1988. Protection of cattle against Rinderpest with Vaccinia virus recombinants expressing the HA or F gene. *Science* 242: 1058-1061.

Zakhartchouk, A. N.; Pyne, C.; Mutwiri, G. K.; Papp, Z.; Baca-Estrada, M. E.; Griebel, P.; Babiuk, L. A.; Tikoo, S. K. 1999. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. *Journal of General Virology* 80: 1263-1269.


Zhou, X.; Berglund, P.; Rhodes, G.; Parker, S. E.; Jondal, M.; Liljestrom, P. 1994. Self-replicating Semliki Forest virus RNA as recombinant vaccine. *Vaccine* 12: 1510-1514

Zhou, X.; Berglund, P.; Zhao, H.; Liljestrom, P.; Jondal, M. 1995. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. *Proceedings of the National Academy of Science of the United States of America* 92: 3009-3013.




Addendum

Oligonucleotides coding for the twelve amino acid RVLAIERYLKDL epitope of glycoprotein 120 of HIV subtype C was cloned into the 177 amino acid site of VP7mt144/177/200. A single epitope was inserted creating VP7mt144/177-R1/200. This new construct was subjected to subsequent insertions of the same peptide to create up to four copies of the epitope in the original VP7mt144/177/200 construct. The constructs containing one (VP7mt144/177-R1/200) and four (VP7mt144/177-R4/200) copies of the insert were expressed in Sf9 cells.



4% Agarose gel electrophoresis of *Pst*I and *Xho*I restriction endonuclease digestions of the new constructs. Lane 1 represents the 100 bp DNA Ladder. Lane 2 contains VP7mt144/177/200, whereas lane 3 contains VP7mt144/177-R1/200. Lane 4 contains VP7mt144/177-R2/200 and lanes 5 and 6 contain VP7mt144/177-R3/200 and VP7mt144/177-R4/200 respectively.



A 15% SDS-PAGE analysis of the new recombinants. Lane 1 represents the protein size marker. Lane 2 and 3 contain proteins from a mock infection and wild-type baculovirus-infected cells respectively. Lane 4 contains expressed VP7 and lane 5 contains the lysate of cells infected with baculovirus expressing the recombinant VP7mt144/177/200. Lane 6 contains VP7mt144/177-R1/200 and lane 8 contains VP7mt144/177-R4/200

Nucleotide sequence of VP7mt144/177-R1/200 (1134 bp)

ATGGACGCGATA CGAGCAAGAGCCTTGTCCGTTGTACGGGCATGTTCACAGTGACAGATGCGAG
 AGTTAGTTGGATCCAGGAGTGTAGGGAGACGTTAGGGATTGCAATCAATAGGTATAATGGTTAA
 CAAATCATTGGTATCGATGAGGCCACAAACCCAAGCAGAACGAAATGAAATGTTTTATGTGT
 ACTGATATGGTTTAGCGGCGCTGAACGTCAAATTGGAAATATTCACCAGATTATGATCAAGCG
 TTGGCAACTGTGGGAGCTCTCGCAACGACTGAAATTCCATATAATGTCAGGCCATGAATGACATC
 GTTACAATAACGGGTAGATGCAAACATTGGACCAAGCAGAACGAAATGCAAACGGGGCCTATGCAGG
 AGCGGTTGAGGTGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCCCTCGAGCAAGGT
 CGAACCGCGTGGTGGGTACATCAATTCAAATTGCAAGTGTGTATGGATGCAAGGTGCTGCGGG
 ACAGGTCAATGCGCTGCTAGCCCCAAGGCTGCATAGAGTCTGGCTATAGAGAGATA CCTAAAGGA
TCTGCAGGGCGCGCAGGGGGACGCAGTCATGATCTATTGCGTTGGAGACCGTTGCGTATATTG
 TGATCCTCAAGGTGCGAAGCTTCTAGAGTCGACTCACTTGAGAGCGCTCCAGGAACCTTTGTCA
 CCGTTGATGGAGTAATGTCAGCTGGAGATGTCGTCGATGGAATACTATTGCAACCAGTGAATG
 TTGGAAATCCTGGGGCACGCAGATCAATTTCAGTTGAAGTGTATGGTATACGTCCGGATA
 GATCGCTAGACACGGTCCCGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGTCTCCCA
 CTTGGCACGCATTACGCGCTGTCATTTCAGCAGATGAATATGCAAGCCTATTAAATCCGCCATT
 TCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATGTGTATGC
 GGCTTGAGACCAGATTCAAGAATGAATGGTGTGCGCCAGTAGGCCAGATTAACAGAGCTCT
 TGTGCTAGCAGCCTACCAC

Amino acid sequence of VP7mt144/177-R1/200 (378 amino acids)

MDAIRARALS VVRACVTVDARVSLDPGMETLGIAINRYNGLTNHSVSMR
 PQTQAERNEMFFMCTDMVLAALNVQIGNISPDYDQALATVGALATTEIPYN
 VQAMNDIVRITGQMQTFGPSKVQTGPYAGAVEVQQSGRYYVPPGEFLEQGR
 TRGGYINSNIAEVCMDAGAACGQVNALLAPRLH**RVLAIERYLKDL**QARRGDA
 VMIYFVWRPLRIFCDPQGAKLSRVDSLESAPGTFVTVDGVNVAAAGDVVAWN
 TIAPVN VGNPGARRSILQFEVLWYTSLDRSLDTVPELAPTLTRCYAYVSPT
 WHALRAVI FQQNMQPINPPIFPPTERNEIVAYLLVASLADVYAALRPDFR
 MNGVVAPVGQINRALVLAAYH

Nucleotide sequence of VP7mt144/177-R4/200 (1251 bp)

ATGGACGCGATA CGAGCAAGAGCCTTGTCCGTTGTACGGGCATGTTCACAGTGACAGATGCGAG
 AGTTAGTTGGATCCAGGAGTGTAGGGAGACGTTAGGGATTGCAATCAATAGGTATAATGGTTAA
 CAAATCATTGGTATCGATGAGGCCACAAACCCAAGCAGAACGAAATGAAATGTTTTATGTGT
 ACTGATATGGTTTAGCGGCGCTGAACGTCAAATTGGAAATATTCACCAGATTATGATCAAGCG
 TTGGCAACTGTGGGAGCTCTCGCAACGACTGAAATTCCATATAATGTCAGGCCATGAATGACATC
 GTTACAATAACGGGTAGATGCAAACATTGGACCAAGCAGAACGAAACGGGGCCTATGCAGG
 AGCGGTTGAGGTGCAACAACTGGCAGATATTACGTACCGCCCCGGGAATTCCCTCGAGCAAGGT
 CGAACCGCGTGGTGGGTACATCAATTCAAATTGCAAGTGTGTATGGATGCAAGGTGCTGCGGG
 ACAGGTCAATGCGCTGCTAGCCCCAAGGCTGCATAGAGTCTGGCTATAGAGAGATA CCTAAAGGA
*TCTGCATAGAGTCTGGCTATAGAGAGATA CCTAAAGGA*TCTGCATAGAGTCTGGCTATAGAGAGA
*TACCTAAAGGATCTGCATAGAGTCTGGCTATAGAGAGATA CCTAAAGGA*TCTGCAGGCCGCGAGG
 GGGGACGCAGTCATGATCTATTGCGTTGGAGACCGTTGCGTATATTGTCACCAGTGAATGGAGTAA
 AAGCTTCTAGAGTCGACTCACTGAGAGCGCTCCAGGAACCTTGTCAACCAGTGAATGGAGTAA
 TGTGCAAGCTGGAGATGTCGTCGATGGAATACTATTGCAACCAGTGAATGGAAATCCTGGGGC
 ACGCAGATCAATTACAGTTGAAGTGTATGGTATACGTCCGGATAGATCGCTAGACACGGT

TCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGTCTCTCCACTGGCACGCATTACG
CGCTGTCACTTTCAGCAGATGAATATGCAGCCTATTAAATCCGCCGATTTCCACCGACTGAAAG
GAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATGTATGCGGCTTGAGACCAGA
TTTCAGAACATGAATGGTGTGTCGCCAGTAGGCCAGATTAAACAGAGCTCTGTGCTAGCAGCCTA
CCAC

Amino acid sequence of VP7mt144/177-R4/200 (417 amino acids)

MDAIRARALSVVVRACVTVDARVSLDPGMETLGIAINRYNGLTNHSVSMRPQTQAERNEMFFMCTD
MVLAALNVQIGNISPDYDQALATVGALATTEIPYNVQAMNDIVRITGQMQTFGPSKVQTGPYAGAVE
VQQSGRYYVPPGEFLEQGRTRGGYINSNIAEVCMMDAGAAGQVNALLAPRLHRVLAIERYLKDLHRV
LAIERYLKDLHRVLAIERYLKDLQARRGDAVMIFYVWRPLRIFCDPQGAKLSR
VDSLESAPGTFVTVDGVNVAAGDVVAWNTIAPVNNGNPARRSILQFEVLWYTSLRSLDTVPELAPT
LTRCYAYVSPTWHALRAVIFQQMNMQPINPPFPTERNEIVAYLLVASLADVYAAALRPDFRMNGVVA
PVGQINRALVLAAYH

Appendices

Appendix A. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7 with VP7mt144/177/200.

VP7	GTTTAAATTGGTAGGATGGACCGATA CGAGCAAGAGCCTGTCCGTTGTACGGCA	42
	M D A I R A R A L S V V R A	14
mt144/177/200	GTTTAAATTGGTAGGATGGACCGATA GCAGCAAGAGCCTGTCCGTTGTACGGCA	42
	M D A I A A R A L S V V R A	14
	*****	*****
VP7	TGTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGTGGAGACGTTAGGG	102
	C V T V T D A R V S L D P G V M E T L G	34
mt144/177/200	TGTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGTGGAGACGTTAGGG	102
	C V T V T D A R V S L D P G V M E T L G	34
	*****	*****
VP7	ATTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACC	162
	I A I N R Y N G L T N H S V S M R P Q T	54
mt144/177/200	ATTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACC	162
	I A I N R Y N G L T N H S V S M R P Q T	54
	*****	*****
VP7	CAAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTAGCGCGCTGAAC	222
	Q A E R N E M F F M C T D M V L A A L N	74
mt144/177/200	CAAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTAGCGCGCTGAAC	222
	Q A E R N E M F F M C T D M V L A A L N	74
	*****	*****
VP7	GTCCAATTGGAAATATTCACCAGATTATGATCAAGCGTGGCAACTGTGGAGCTCTC	282
	V Q I G N I S P D Y D Q A L A T V G A L	94
mt144/177/200	GTCCAATTGGAAATATTCACCAGATTATGATCAAGCGTGGCAACTGTGGAGCTCTC	282
	V Q I G N I S P D Y D Q A L A T V G A L	94
	*****	*****
VP7	GCAACGACTGAAATTCCATATAATGTTCAAGGCCATGAATGACATCGTTAGAATAACGGGT	342
	A T T E I P Y N V Q A M N D I V R I T G	114
mt144/177/200	GCAACGACTGAAATTCCATATAATGTTCAAGGCCATGAATGACATCGTTAGAATAACGGGT	342
	A T T E I P Y N V Q A M N D I V R I T G	114
	*****	*****
VP7	CAGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAG	402
	Q M Q T F G P S K V Q T G P Y A G A V E	134
mt144/177/200	CAGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAG	402
	Q M Q T F G P S K V Q T G P Y A G A V E	134
	*****	*****
VP7	GTGCAACAATCTGGCAGATATTACGTACCG-----CAAGGTCGAACG	444
	V Q Q S G R Y Y V P -----Q G R T	148
mt144/177/200	GTGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCTCGAGCAAGGTCGAACG	462
	V Q Q S G R Y Y V P P G E F L E Q G R T	154
	*****	*****
VP7	CGTGGTGGGTACATCAAATATTGCAGAAGTGTGTATGGATGCAGGTGCTGCGGGA	504
	R G G Y I N S N I A E V C M D A G A A G	168
mt144/177/200	CGTGGTGGGTACATCAAATATTGCAGAAGTGTGTATGGATGCAGGTGCTGCGGGA	522
	R G G Y I N S N I A E V C M D A G A A G	174
	*****	*****



VP7	CAGGTCAATGCGCTGCTAGCCCCAAGG-----	AGGGGGGACGCAGTC	556
mt144/177/200	Q V N A L L A P R R G D A V 182	CAGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAGGCCGCGCAGGGGGGACGCAGTC	582
	Q V N A L L A P R L Q R P A R R G D A V 194	*****	*****
VP7	ATGATCTATTCGTTGGAGACCGTTCGCTATATTGTGATCCTCAAGGTGCG-----	610	
mt144/177/200	M I Y F V W R P L R I F C D P Q G A 200	ATGATCTATTCGTTGGAGACCGTTCGCTATATTGTGATCCTCAAGGTGCGAAGCTT 642	*****
	M I Y F V W R P L R I F C D P Q G A K L 214	*****	*****
VP7	-----TCACTTGAGAGCGCTCCAGGAACCTTTGTCAACCGTTGATGGAGTAAAT	658	
mt144/177/200	S L E S A P G T F V T V D G V N 216	TCTAGAGTCGACTCACCTGAGAGCGCTCCAGGAACCTTTGTCAACCGTTGATGGAGTAAAT	702
	S R V D S L E S A P G T F V T V D G V N 234	*****	*****
VP7	GTTGCAGCTGGAGATGTCGTCGCATGGAATACTATTGCACCAGTGAATGTTGAAATCCT	718	
mt144/177/200	V A A G D V V A W N T I A P V N V G N P 236	GTTGCAGCTGGAGATGTCGTCGCATGGAATACTATTGCACCAGTGAATGTTGAAATCCT	762
	V A A G D V V A W N T I A P V N V G N P 254	*****	*****
VP7	GGGGCACGCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCG	778	
mt144/177/200	G A R R S I L Q F E V L W Y T S L D R S 256	GGGGCACGCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCG	822
	G A R R S I L Q F E V L W Y T S L D R S 274	*****	*****
VP7	CTAGACACGGTTCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGCTCTCCC	798	
mt144/177/200	L D T V P E L A P T L T R C Y A Y V S P 276	CTAGACACGGTTCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGCTCTCCC	882
	L D T V P E L A P T L T R C Y A Y V S P 294	*****	*****
VP7	ACTTGGCACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGCAGCCTATTAATCCG	858	
mt144/177/200	T W H A L R A V I F Q Q M N M Q P I N P 296	ACTTGGCACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGCAGCCTATTAATCCG	942
	T W H A L R A V I F Q Q M N M Q P I N P 314	*****	*****
VP7	CCGATTTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTTA	918	
mt144/177/200	P I F P P T E R N E I V A Y L L V A S L 316	CCGATTTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTTA	1002
	P I F P P T E R N E I V A Y L L V A S L 334	*****	*****
VP7	GCTGATGTATGCGGCTTGAGACCAGATTCAGAACATGAATGGTGTGCGGCCAGTA	978	
mt144/177/200	A D V Y A A L R P D F R M N G V V A P V 336	GCTGATGTATGCGGCTTGAGACCAGATTCAGAACATGAATGGTGTGCGGCCAGTA	1062
	A D V Y A A L R P D F R M N G V V A P V 354	*****	*****
VP7	GGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGTGGCTGCCGTGTCACG	1020	
mt144/177/200	G Q I N R A L V L A A Y H Stop 349	GGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGTGGCTGCCGTGTCACG	1104
	G Q I N R A L V L A A Y H Stop 367	*****	*****

Appendix B-1. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VPmt144/177-A/200.

mt144/177/200	GT	TTAAATT	CGGTTAGGATGGACGCGATAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M	D A I A A R A L S V V R A C	15	
mt144/177-A/200	GT	TTAAATT	CGGTTAGGATGGACGCGATAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M	D A I A A R A L S V V R A C	15	

mt144/177/200	G	T GTCACAGT	GACAGATGCGAGAGTTAGTTGGATCCAGGAGTGTAGGGAGACGTTAGGGA	103
	V	T V T D A R V S L D P G V M E T L G I	35	
mt144/177-A/200	G	T GTCACAGT	GACAGATGCGAGAGTTAGTTGGATCCAGGAGTGTAGGGAGACGTTAGGGA	103
	V	T V T D A R V S L D P G V M E T L G I	35	

mt144/177/200	T	TGCAATCAATAGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163	
	A	I N R Y N G L T N H S V S M R P Q T Q	55	
mt144/177-A/200	T	TGCAATCAATAGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163	
	A	I N R Y N G L T N H S V S M R P Q T Q	55	

mt144/177/200	A	AGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTAGCGGCGCTGAACG	223	
	A	E R N E M F F M C T D M V L A A L N V	75	
mt144/177-A/200	A	AGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTAGCGGCGCTGAACG	223	
	A	E R N E M F F M C T D M V L A A L N V	75	

mt144/177/200	T	TCAAATTGGAAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283	
	Q	I G N I S P D Y D Q A L A T V G A L A	95	
mt144/177-A/200	T	TCAAATTGGAAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283	
	Q	I G N I S P D Y D Q A L A T V G A L A	95	

mt144/177/200	C	AACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343	
	T	T E I P Y N V Q A M N D I V R I T G Q	115	
mt144/177-A/200	C	ACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343	
	T	T E I P Y N V Q A M N D I V R I T G Q	115	

mt144/177/200	A	AGATGCAAACATTGGACCAAGCAAAGTGCACACGGGGCTTATGCAGGAGCGGTTGAGG	403	
	M	Q T F G P S K V Q T G P Y A G A V E V	135	
mt144/177-A/200	A	AGATGCAAACATTGGACCAAGCAAAGTGCACACGGGGCTTATGCAGGAGCGGTTGAGG	403	
	M	Q T F G P S K V Q T G P Y A G A V E V	135	

mt144/177/200	T	TGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCTCGAGCAAGGTCGAACGC	463	
	Q	Q S G R Y Y V P P G E F L E Q G R T R	155	
mt144/177-A/200	T	TGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCTCGAGCAAGGTCGAACGC	463	
	Q	Q S G R Y Y V P P G E F L E Q G R T R	155	

mt144/177/200	G	GTTGGGTACATCAAATTGCAGAAGTGTGTATGGATGCAGGTGCTCGGGAC	523	
	G	G Y I N S N I A E V C M D A G A A G Q	175	
mt144/177-A/200	G	GTTGGGTACATCAAATTGCAGAAGTGTGTATGGATGCAGGTGCTCGGGAC	523	
	G	G Y I N S N I A E V C M D A G A A G Q	175	

mt144/177/200	A	AGGTCAATGCGCTGCTAGCCCCAAGG-----	561	
	V	N A L L A P R	187	



mt144/177-A/200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCATAAGAAGAAAGAAGAGGGTGAGGATGATA	583
	V N A L L A P R L H K K K E E G E D D T	195

mt144/177/200	-----CTGCAGGCGCGCAGGGGGACGCAGTCATGA	592
	L Q A R R G D A V M I	198
mt144/177-A/200	CTGCTCGACAGGAGATAAGAAAAGCATGGCTGCAGGCGCGCAGGGGGACGCAGTCATGA	643
	A R Q E I R K A W L Q A R R G D A V M I	215

mt144/177/200	TCTATTCGTTGGAGACC GTT GCGTATATTGTGATCCTCAAGGTGCGAAGCTT CTA	612
	Y F V W R P L R I F C D P Q G A K L S R	218
mt144/177-A/200	TCTATTCGTTGGAGACC GTT GCGTATATTGTGATCCTCAAGGTGCGAAGCTT CTA	703
	Y F V W R P L R I F C D P Q G A K L S R	235

mt144/177/200	GAGTCGACTCACTTGAGAGCGCTCCAGGAAC TTT GTCACCGTTGATGGAGTAAATGTTG	672
	V D S L E S A P G T F V T V D G V N V A	238
mt144/177-A/200	GAGTCGACTCACTTGAGAGCGCTCCAGGAAC TTT GTCACCGTTGATGGAGTAAATGTTG	763
	V D S L E S A P G T F V T V D G V N V A	255

mt144/177/200	CAGCTGGAGATGTCGTCGCATGGAATACTATTG CACCAGTGAATGTTGGAAATCCTGGGG	732
	A G D V V A W N T I A P V N V G N P G A	258
mt144/177-A/200	CAGCTGGAGATGTCGTCGCATGGAATACTATTG CACCAGTGAATGTTGGAAATCCTGGGG	823
	A G D V V A W N T I A P V N V G N P G A	275

mt144/177/200	CACGCAGATCAATTTACAGTTGAAGTGTATGGTATACGT CCTT GGATAGATCGCTAG	792
	R R S I L Q F E V L W Y T S L D R S L D	278
mt144/177-A/200	CACGCAGATCAATTTACAGTTGAAGTGTATGGTATACGT CCTT GGATAGATCGCTAG	883
	R R S I L Q F E V L W Y T S L D R S L D	295

mt144/177/200	ACACGGTTCCGGATTGGCTCCAACGCTCACAGATGTTATGCGTATGTCCTCCC ACTT	852
	T V P E L A P T L T R C Y A Y V S P T W	298
mt144/177-A/200	ACACGGTTCCGGATTGGCTCCAACGCTCACAGATGTTATGCGTATGTCCTCCC ACTT	943
	T V P E L A P T L T R C Y A Y V S P T W	315

mt144/177/200	GGCACGCATTACGCGCTGT CATTTCAGCAGATGAATATGCAGCCTATTAATCCGCCGA	912
	H A L R A V I F Q Q M N M Q P I N P P I	318
mt144/177-A/200	GGCACGCATTACGCGCTGT CATTTCAGCAGATGAATATGCAGCCTATTAATCCGCCGA	1003
	H A L R A V I F Q Q M N M Q P I N P P I	335

mt144/177/200	TTTTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTG	972
	F P P T E R N E I V A Y L L V A S L A D	338
mt144/177-A/200	TTTTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTG	1063
	F P P T E R N E I V A Y L L V A S L A D	355

mt144/177/200	ATGTGTATCGGGCTTGAGACCAGATTCAGAACATGAATGGTGTGCGCCAGTAGGCC	1032
	V Y A A L R P D F R M N G V V A P V G Q	358
mt144/177-A/200	ATGTGTATCGGGCTTGAGACCAGATTCAGAACATGAATGGTGTGCGCCAGTAGGCC	1123
	V Y A A L R P D F R M N G V V A P V G Q	375

mt144/177/200	AGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGTGGCTCGGTGTTGCACGGTCA	1070
	I N R A L V L A A Y H Stop	369
mt144/177-A/200	AGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGTGGCTCGGTGTTGCACGGTCA	1161
	I N R A L V L A A Y H Stop	386

Appendix B-2. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144-B/177/200.

mt144/177/200	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
mt144-B/177/200	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
	*****	*****
mt144/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
mt144-B/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
	*****	*****
mt144/177/200	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
mt144-B/177/200	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
	*****	*****
mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGACTGATATGGTTAGCGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
mt144-B/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGACTGATATGGTTAGCGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
	*****	*****
mt144/177/200	TCCAAATTGGAATATTCAACCAGATTATGATCAAGCGTTGGCAACTGTGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
mt144-B/177/200	TCCAAATTGGAATATTCAACCAGATTATGATCAAGCGTTGGCAACTGTGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
	*****	*****
mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
mt144-B/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
	*****	*****
mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135
mt144-B/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135
	*****	*****
mt144/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCCAGGGAAATTCTCGAG-----	450
	Q Q S G R Y Y V P P G E F L E	150
mt144-B/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCCAGGGAAATTCTCGAGGTAGACGTTGATC	463
	Q Q S G R Y Y V P P G E F L E V D V D P	155
	*****	*****
mt144/177/200	-----	450
	150	
mt144-B/177/200	CAAATAAGGTAAGTGGAAAGAACATATAAAAGAGGTAACCGAAAAATTATTGAAAGCGG	523
	N K G K W K E H I K E V T E K L L K A V	175
	*****	*****
mt144/177/200	-----CAAGGTCGAACCGCGTGGTGGGTACATCAAATATTGCAGAAGTGTATGG	505
	E Q G R T R G G Y I N S N I A E V C M D	170



mt144-B/177/200	TCGAGCAAGGTCGAACCGTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTGTATGG	583
	E Q G R T R G G Y I N S N I A E V C M D	195
	*****	*****
mt144/177/200	ATGCAGGTGCTGCCGGACAGGTCAATGCCTGCTAGCCCCAAGGCTGCAGAGGCCTGC	565
	A G A A G Q V N A L L A P R L Q R P A R	190
mt144-B/177/200	ATGCAGGTGCTGCCGGACAGGTCAATGCCTGCTAGCCCCAAGGCTGCAGAGGCCTGC	643
	A G A A G Q V N A L L A P R L Q R P A R	215
	*****	*****
mt144/177/200	GCAGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTTGTGATC	625
	R G D A V M I Y F V W R P L R I F C D P	210
mt144-B/177/200	GCAGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTTGTGATC	703
	R G D A V M I Y F V W R P L R I F C D P	235
	*****	*****
mt144/177/200	CTCAAGGTGCGAAGCTTCTAGAGTCGACTCACTTGAGAGCGCTCCAGGAACCTTTGTCA	685
	Q G A K L S R V D S L E S A P G T F V T	230
mt144-B/177/200	CTCAAGGTGCGAAGCTTCTAGAGTCGACTCACTTGAGAGCGCTCCAGGAACCTTTGTCA	763
	Q G A K L S R V D S L E S A P G T F V T	255
	*****	*****
mt144/177/200	CCGTTGATGGAGTAAATGTTGAGCTGGAGATGTCGTCGATGGAATACTATTGACCAAG	745
	V D G V N V A A G D V V A W N T I A P V	250
mt144-B/177/200	CCGTTGATGGAGTAAATGTTGAGCTGGAGATGTCGTCGATGGAATACTATTGACCAAG	823
	V D G V N V A A G D V V A W N T I A P V	275
	*****	*****
mt144/177/200	TGAATGTTGGAAATCCTGGGGCACGCAGATCAATTACAGTTGAAGTGTATGGTATA	805
	N V G N P G A R R S I L Q F E V L W Y T	270
mt144-B/177/200	TGAATGTTGGAAATCCTGGGGCACGCAGATCAATTACAGTTGAAGTGTATGGTATA	883
	N V G N P G A R R S I L Q F E V L W Y T	295
	*****	*****
mt144/177/200	CGTCCTTGGATAGATCGCTAGACACGGTCCCGAATTGGCTCCAACGCTCACAGATGTT	865
	S L D R S L D T V P E L A P T L T R C Y	290
mt144-B/177/200	CGTCCTTGGATAGATCGCTAGACACGGTCCCGAATTGGCTCCAACGCTCACAGATGTT	943
	S L D R S L D T V P E L A P T L T R C Y	315
	*****	*****
mt144/177/200	ATGCGTATGTCCTCCCACCTGGCACGCATTACGCGCTGTCACTTTCAGCAGATGAATA	925
	A Y V S P T W H A L R A V I F Q Q M N M	310
mt144-B/177/200	ATGCGTATGTCCTCCCACCTGGCACGCATTACGCGCTGTCACTTTCAGCAGATGAATA	1003
	A Y V S P T W H A L R A V I F Q Q M N M	335
	*****	*****
mt144/177/200	TGCAGCCTATTAATCCGCCATTTCACCGACTGAAAGGAATGAAATTGTTGCGTATC	985
	Q P I N P P I F P P T E R N E I V A Y L	330
mt144-B/177/200	TGCAGCCTATTAATCCGCCATTTCACCGACTGAAAGGAATGAAATTGTTGCGTATC	1063
	Q P I N P P I F P P T E R N E I V A Y L	355
	*****	*****
mt144/177/200	TATTAGTAGCTTCTTAGCTGATGTATGCGGCTTGAGACCAAGATTCAGAATGAATG	1045
	L V A S L A D V Y A A L R P D F R M N G	350
mt144-B/177/200	TATTAGTAGCTTCTTAGCTGATGTATGCGGCTTGAGACCAAGATTCAGAATGAATG	1123
	L V A S L A D V Y A A L R P D F R M N G	375
	*****	*****
mt144/177/200	GTGTTGTCGCCAGTAGGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGT	1104
	V V A P V G Q I N R A L V L A A Y H Stop	368
mt144-B/177/200	GTGTTGTCGCCAGTAGGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACCACTAGT	1182
	V V A P V G Q I N R A L V L A A Y H Stop	393
	*****	*****

Appendix B-3. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144-B/177-A/200.

mt144/177/200	GTTTAAATCGGTTAGGATGGACCGATAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
mt144-B/177-A/	GTTTAAATCGGTTAGGATGGACCGATAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
	*****	*****
mt144/177/200	GTCGACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
mt144-B/177-A/	GTCGACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
	*****	*****
mt144/177/200	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
mt144-B/177-A/	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
	*****	*****
mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTACTGATATGGTTAGCGGGCCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
mt144-B/177-A/	AAGCAGAACGAAATGAAATGTTTTATGTACTGATATGGTTAGCGGGCCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
	*****	*****
mt144/177/200	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTGGCAACTGTGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
mt144-B/177-A/	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTGGCAACTGTGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
	*****	*****
mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
mt144-B/177-A/	CAACGACTGAAATTCCATATAATGTTCAAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
	*****	*****
mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCACACGGGCCTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135
mt144-B/177-A/	AGATGCAAACATTGGACCAAGCAAAGTGCACACGGGCCTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135
	*****	*****
mt144/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCCCTCGAGGTAGACGTTGATC	450
	Q Q S G R Y Y V P P G E F L E	150
mt144-B/177-A/	TGCAACAATCTGGCAGATATTACGTACCGCCCCGGGAATTCCCTCGAGGTAGACGTTGATC	463
	Q Q S G R Y Y V P P G E F L E V D V D P	155
	*****	*****
mt144/177/200	-----	450
		150
mt144-B/177-A/	CAAATAAGGGTAAGTGGAAAGAACATATAAAAGAGGTAACCGAAAAATTATTGAAAGCGG	523
	N K G K W K E H I K E V T E K L L K A V	175
	-----	505
mt144/177/200	-----CAAGGTCGAACCGTGGTGGTACATCAAATTCAAATATTGCAGAAGTGTGTATGG	505
	E Q G R T R G G Y I N S N I A E V C M D	170



mt144-B/177-A/	TCGAGCAAGGTGCGAACCGCTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTGTATGG	583
	E Q G R T R G G Y I N S N I A E V C M D	195
	*****	*****
mt144/177/200	ATGCAGGTGCTGCCGACAGGTCAATGCCTGCTAGCCCCAAGG-----	549
	A G A A G Q V N A L L A P R	184
mt144-B/177-A/	ATGCAGGTGCTGCCGACAGGTCAATGCCTGCTAGCCCCAAGGCTGCATAAGAAGAAAG	643
	A G A A G Q V N A L L A P R L H K K K E	215
	*****	*****
mt144/177/200	-----CTGCAGGCGCGCA	562
	L Q A R R	189
mt144-B/177-A/	AAGAGGGTGAGGATGATACTGCTCGACAGGAGATAAGAAAAGCATGGCTGCAGGCGCGCA	703
	E G E D D T A R Q E I R K A W L Q A R R	235
	*****	*****
mt144/177/200	GGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTTGTGATCCTC	622
	G D A V M I Y F V W R P L R I F C D P Q	209
mt144-B/177-A/	GGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTTGTGATCCTC	763
	G D A V M I Y F V W R P L R I F C D P Q	255
	*****	*****
mt144/177/200	AAGGTGCGAAGCTTCTAGAGTCACTCACTTGAGAGCGCTCCAGGAACCTTGTACCG	682
	G A K L S R V D S L E S A P G T F V T V	229
mt144-B/177-A/	AAGGTGCGAAGCTTCTAGAGTCACTCACTTGAGAGCGCTCCAGGAACCTTGTACCG	823
	G A K L S R V D S L E S A P G T F V T V	275
	*****	*****
mt144/177/200	TTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGCATGGAATACTATTGCACCAAGTGA	742
	D G V N V A A G D V V A W N T I A P V N	249
mt144-B/177-A/	TTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGCATGGAATACTATTGCACCAAGTGA	883
	D G V N V A A G D V V A W N T I A P V N	295
	*****	*****
mt144/177/200	ATGTTGGAAATCCTGGGCACGCAGATCAATTACAGTTGAAGTGTATGGTATACGT	802
	V G N P G A R R S I L Q F E V L W Y T S	269
mt144-B/177-A/	ATGTTGGAAATCCTGGGCACGCAGATCAATTACAGTTGAAGTGTATGGTATACGT	943
	V G N P G A R R S I L Q F E V L W Y T S	315
	*****	*****
mt144/177/200	CCTTGGATAGATCGCTAGACACGGTCCGGAATTGGCTCCAACGCTCACAGATGTTATG	862
	L D R S L D T V P E L A P T L T R C Y A	289
mt144-B/177-A/	CCTTGGATAGATCGCTAGACACGGTCCGGAATTGGCTCCAACGCTCACAGATGTTATG	1003
	L D R S L D T V P E L A P T L T R C Y A	335
	*****	*****
mt144/177/200	CGTATGTCCTCCCACTTGGCACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGC	922
	Y V S P T W H A L R A V I F Q Q M N M Q	309
mt144-B/177-A/	CGTATGTCCTCCCACTTGGCACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGC	1063
	Y V S P T W H A L R A V I F Q Q M N M Q	355
	*****	*****
mt144/177/200	AGCCTATTAATCCGCCGATTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTAT	982
	P I N P P I F P P T E R N E I V A Y L L	329
mt144-B/177-A/	AGCCTATTAATCCGCCGATTTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTAT	1123
	P I N P P I F P P T E R N E I V A Y L L	375
	!	*****
mt144/177/200	TAGTAGCTCTTAGCTGATGTGTATGCGGCTTGAGACAGATTCAGAATGAATGGTG	1042
	V A S L A D V Y A A L R P D F R M N G V	349
mt144-B/177-A/	TAGTAGCTCTTAGCTGATGTGTATGCGGCTTGAGACAGATTCAGAATGAATGGTG	1183
	V A S L A D V Y A A L R P D F R M N G V	395
	*****	*****



mt144/177/200	TTGTCGCCAGTAGGCCAGATTAACAGAGCTTTGTGCTAGCAGCCTACCACTAGTGGC	1102
	V A P V G Q I N R A L V L A A Y H Stop	366
mt144-B/177-A/	TTGTCGCCAGTAGGCCAGATTAACAGAGCTTTGTGCTAGCAGCCTACCACTAGTGGC	1239
	V A P V G Q I N R A L V L A A Y H Stop	412

Appendix C-1. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144/177-100/200.

mt144/177/200	GTTTAAATTGGTTAGGATGGACGCGATA	CAGCAAGAGCCTTGTCCGTTACGGGCAT	43
	M D A I A A R A L S V V R A C		15
mtVP7/VP2-100	GTTTAAATTGGTTAGGATGGACGCGATA	CAGCAAGAGCCTTGTCCGTTACGGGCAT	43
	M D A I A A R A L S V V R A C		15

mt144/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGT	GATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I		35
mtVP7/VP2-100	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGT	GATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I		35

mt144/177/200	TTGCAATCAATAGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163	
	A I N R Y N G L T N H S V S M R P Q T Q		55
mtVP7/VP2-100	TTGCAATCAATAGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163	
	A I N R Y N G L T N H S V S M R P Q T Q		55

mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGCCTGAAACG	223	
	A E R N E M F F M C T D M V L A A L N V		75
mtVP7/VP2-100	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGCCTGAAACG	223	
	A E R N E M F F M C T D M V L A A L N V		75

mt144/177/200	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGAGCTCTCG	283	
	Q I G N I S P D Y D Q A L A T V G A L A		95
mtVP7/VP2-100	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGAGCTCTCG	283	
	Q I G N I S P D Y D Q A L A T V G A L A		95

mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343	
	T T E I P Y N V Q A M N D I V R I T G Q		115
mtVP7/VP2-100	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343	
	T T E I P Y N V Q A M N D I V R I T G Q		115

mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCAAACGGGCCTTATGCAGGAGCGGTTGAGG	403	



	M Q T F G P S K V Q T G P Y A G A V E V	135
mtVP7/VP2-100	AGATGCAAACATTGGACCAAGCAAAGTGCACACGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135
	*****	*****
mt144/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCC GGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155
mtVP7/VP2-100	TGCAACAATCTGGCAGATATTACGTACCGCCC GGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155
	*****	*****
mt144/177/200	GTGGTGGGTACATCAAATATTGCAGAAGTGTATGGATGCAGGTGCTGCGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175
mtVP7/VP2-100	GTGGTGGGTACATCAAATATTGCAGAAGTGTATGGATGCAGGTGCTGCGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175
	*****	*****
mt144/177/200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAGGCCCT-----	561
	V N A L L A P R L Q R P	187
mtVP7/VP2-100	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGTTGATTTTGACAACATCGTCATG	583
	V N A L L A P R L Q F D F L T T F V H A	195
	*****	*****
mt144/177/200	-----.	561
		187
mtVP7/VP2-100	CGAAGAAGAAAGAAGAGGGTGAGGATGATACTGCTGACAGGAGATAAGAAAAGCATGG	643
	K K K E E G E D D T A R Q E I R K A W V	215
	*****	*****
mt144/177/200	-----	561
		187
mtVP7/VP2-100	TTAAGGGGATGCCTTATATGGATTCTCAAAACCGATGAAAATACGCGTGGATTCAACA	703
	K G M P Y M D F S K P M K I T R G F N R	235
	*****	*****
mt144/177/200	-----	561
		187
mtVP7/VP2-100	GAAATATGCTTTCCTTGCAGCGCTCGATTCAATTGAGAAAGAGGAACGGTAGATGTTG	763
	N M L F L A A L D S F R K R N G V D V D	255
	*****	*****
mt144/177/200	-----	561

mtVP7/VP2-100 ATCCGAATAAGGGTAAGTGGAAAGAACATATAAAGGAGGTAAACCGAAAAATTGAAGAAAG 823
 P N K G K W K E H I K E V T E K L K K A 275

mt144/177/200 -----GCGCGCAGGGGGGACGCAGTCATGATCT 589
 A R R G D A V M I Y 197
 mtVP7/VP2-100 CGCAAACGAAAATGGAGGACAACCATGCCAAGCGCGCAGGGGGACGCAGTCATGATCT 883
 Q T E N G G Q P C Q A R R G D A V M I Y 295

mt144/177/200 ATTCGTTGGAGACCGTTGCGTATATTTGTGATCCTCAAGGTGCGAAGCTTTCTAGAG 649
 F V W R P L R I F C D P Q G A K L S R V 117
 mtVP7/VP2-100 ATTCGTTGGAGACCGTTGCGTATATTTGTGATCCTCAAGGTGCGAAGCTTTCTAGAG 943
 F V W R P L R I F C D P Q G A K L S R V 315

mt144/177/200 TCGACTCACTTGAGAGCGCTCCAGGAACCTTGTGACCGTTGATGGAGTAAATGTTGCAG 709
 D S L E S A P G T F V T V D G V N V A A 137
 mtVP7/VP2-100 TCGACTCACTTGAGAGCGCTCCAGGAACCTTGTGACCGTTGATGGAGTAAATGTTGCAG 1003
 D S L E S A P G T F V T V D G V N V A A 335

mt144/177/200 CTGGAGATGTCGTCGCATGGAATACTATTGCACCAAGTGAATGTTGGAAATCCTGGGCAC 769
 G D V V A W N T I A P V N V G N P G A R 157
 mtVP7/VP2-100 CTGGAGATGTCGTCGCATGGAATACTATTGCACCAAGTGAATGTTGGAAATCCTGGGCAC 1063
 G D V V A W N T I A P V N V G N P G A R 355

mt144/177/200 GCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCGCTAGACA 829
 R S I L Q F E V L W Y T S L D R S L D T 177
 mtVP7/VP2-100 GCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCGCTAGACA 1123
 R S I L Q F E V L W Y T S L D R S L D T 375

mt144/177/200 CGGTTCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGTCTCTCCACTTGGC 889
 V P E L A P T L T R C Y A Y V S P T W H 197
 mtVP7/VP2-100 CGGTTCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGTCTCTCCACTTGGC 1183
 V P E L A P T L T R C Y A Y V S P T W H 395

mt144/177/200 ACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGCAGCCTATTAATCCGCCATT 949

	A L R A V I F Q Q M N M Q P I N P P I F	217
mtVP7/VP2-100	ACGCATTACGCGCTGTCA	1243
	T T T CAGCAGATGAATATGCAGCCTATTAA	
	T C C G C C G A T T	
	A L R A V I F Q Q M N M Q P I N P P I F	415
	*****	*****
mt144/177/200	TTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATG	1009
	P P T E R N E I V A Y L L V A S L A D V	237
mtVP7/VP2-100	TTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATG	1303
	P P T E R N E I V A Y L L V A S L A D V	435
	*****	*****
mt144/177/200	TGTATCGGCTTGAGACCAGATTCAGAATGAATGGTGGCTCGGCCAGTAGGCCAGA	1069
	Y A A L R P D F R M N G V V A P V G Q I	257
mtVP7/VP2-100	TGTATCGGCTTGAGACCAGATTCAGAATGAATGGTGGCTCGGCCAGTAGGCCAGA	1363
	Y A A L R P D F R M N G V V A P V G Q I	455
	*****	*****
mt144/177/200	TTAACAGAGCTTTGTGCTAGCAGCCTACCACTAGTGGCTGCGGTGTTGCACGGTCACCG	1104
	N R A L V L A A Y H Stop	267
mtVP7/VP2-100	TTAACAGAGCTTTGTGCTAGCAGCCTACCACTAGTGGCTGCGGTGTTGCACGGTCACCG	1398
	N R A L V L A A Y H Stop	465
	*****	*****

Appendix C-2. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144/177-150/200.

mt144/177/200	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGCAT	43
	M D A I A A R A L S V V R A C	15
mtVP7/VP2-150	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGCAT	43
	M D A I A A R A L S V V R A C	15

mt144/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
mtVP7/VP2-150	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35

mt144/177/200	TTGCAATCAAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
mtVP7/VP2-150	TTGCAATCAAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55

mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
mtVP7/VP2-150	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75

mt144/177/200	TCCAAATTGGAAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
mtVP7/VP2-150	TCCAAATTGGAAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95

mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
mtVP7/VP2-150	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115

mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCAAACGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135



mtVP7/VP2-150	AGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135

mt144/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCCGGGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155
mtVP7/VP2-150	TGCAACAATCTGGCAGATATTACGTACCGCCCGGGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155

mt144/177/200	GTGGTGGGTACATCAAATATTGCAGAAAGTGTATGGATGCAGGTGCTGCGGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175
mtVP7/VP2-150	GTGGTGGGTACATCAAATATTGCAGAAAGTGTATGGATGCAGGTGCTGCGGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175

mt144/177/200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAGGCCT-----	561
	V N A L L A P R L Q R P	187
mtVP7/VP2-150	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAAAGGTCCACTGAATGACTTACGAGTTA	583
	D A K A S A M Y S G K G P L N D L R V K	195

mt144/177/200	-----*	561
		187
mtVP7/VP2-150	AAATTGAGCGGGATGATTATCTGAGAGACAATTATTAGATCATTGAGTACGGTAAGA	643
	I E R D D L S R E T I I Q I I E Y G K K	215

mt144/177/200	-----	561
		187
mtVP7/VP2-150	AATTAAATTCATCAGCAGGTGATAAGCAGGGAACATTCAATTGAAAAATTGGTAGAGT	703
	F N S S A G D K Q G N I S I E K L V E Y	235

mt144/177/200	-----	561
		187
mtVP7/VP2-150	ATTGTGATTTTTGACAACATTGTTCATGCGAAGAAGAAAGAAGGGTGAGGATGATA	763
	C D F L T T F V H A K K K E E G E D D T	255
	!	
mt144/177/200	-----	561
		187



mtVP7/VP2-150	CTGCTCGACAGGAGATAAGAAAAGCATGGGTTAAGGGATGCCTTATATGGATTCCTCAA	823
	A R Q E I R K A W V K G M P Y M D F S K	275
mt144/177/200	-----	561
		187
mtVP7/VP2-150	AACCGATGAAAATCACCGCGTGGATTCAACAGAAATATGCTTTCTGCAGCGCTCGATT	883
	P M K I T R G F N R N M L F L A A L D S	295
mt144/177/200	-----	561
		187
mtVP7/VP2-150	CATTCAGAAAGAGGAACGGGTAGATGTTGATCCGAATAAGGGTAAGTGAAAGAACATA	943
	F R K R N G V D V D P N K G K W K E H I	315
mt144/177/200	-----	561
		187
mtVP7/VP2-150	TAAAGGAGGTAACCGAAAAATTGAAGAAAGCGCAAACGAAAATGGAGGACAACCATGCC	1003
	K E V T E K L K K A Q T E N G G Q P C Q	335
mt144/177/200	--GCGCGCAGGGGGACGCAGTCATGATCTA-----	619
	A R R G D A V M I Y F V W R P L R I F C	207
mtVP7/VP2-150	AAGCGCGCAGGGGGACGCAGTCATGATCTATTCGTTGGAGACCCTGCATATT-----	1063
	A R R G D A V M I Y F V W R P L R I F C	355

mt144/177/200	GTGATCCTCAAGGTGCGAAGCTTTCTAGAGTCGACTCACTTGAGAGCGCTCCAGGAAC	679
	D P Q G A K L S R V D S L E S A P G T F	227
mtVP7/VP2-150	GTGATCCTCAAGGTGCGAAGCTTTCTAGAGTCGACTCACTTGAGAGCGCTCCAGGAAC	1123
	D P Q G A K L S R V D S L E S A P G T F	375

mt144/177/200	TTGTCACCGTTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGATGGAATACTATTG	739
	V T V D G V N V A A G D V V A W N T I A	247
mtVP7/VP2-150	TTGTCACCGTTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGATGGAATACTATTG	1183
	V T V D G V N V A A G D V V A W N T I A	395

mt144/177/200	CACCAAGTGAATGTTGGAAATCCTGGGGCACGCAGATCAATTACAGTTGAAAGTGTAT	799
	P V N V G N P G A R R S I L Q F E V L W	267

mtVP7/VP2-150	CACCA GTGAATGTTGGAAATCCTGGGCACGCAGATCAATTTCAGTTGAAGTGTAT	1243
	P V N V G N P G A R R S I L Q F E V L W	415
	*****	*****
mt144/177/200	GGTATA CGTCCTTGGATAGATCGCTAGACACGGTCCGGATTGGCTCCAACGCTCACAA	859
	Y T S L D R S L D T V P E L A P T L T R	287
mtVP7/VP2-150	GGTATA CGTCCTTGGATAGATCGCTAGACACGGTCCGGATTGGCTCCAACGCTCACAA	1303
	Y T S L D R S L D T V P E L A P T L T R	435
	*****	*****
mt144/177/200	GATGTTATGCGTATGTCTCTCCCAC TTGGCACGCATTACGCGCTGTCA TTTTCAGCAGA	919
	C Y A Y V S P T W H A L R A V I F Q Q M	307
mtVP7/VP2-150	GATGTTATGCGTATGTCTCTCCCAC TTGGCACGCATTACGCGCTGTCA TTTTCAGCAGA	1363
	C Y A Y V S P T W H A L R A V I F Q Q M	455
	*****	*****
mt144/177/200	TGAATATGCAGCCTATTAATCCGCCGATTTTCCACCGACTGAAAGGAATGAAATTGTTG	979
	N M Q P I N P P I F P P T E R N E I V A	327
mtVP7/VP2-150	TGAATATGCAGCCTATTAATCCGCCGATTTTCCACCGACTGAAAGGAATGAAATTGTTG	1423
	N M Q P I N P P I F P P T E R N E I V A	475
	*****	*****
mt144/177/200	CGTATCTATTAGTAGCTTCTTAGCTGATGTGTATGCGGCTTGAGACCAGATTCAGAA	1039
	Y L L V A S L A D V Y A A L R P D F R M	347
mtVP7/VP2-150	CGTATCTATTAGTAGCTTCTTAGCTGATGTGTATGCGGCTTGAGACCAGATTCAGAA	1483
	Y L L V A S L A D V Y A A L R P D F R M	495
	*****	*****
mt144/177/200	TGAATGGTGTGCGGCCAGTAGGCCAGATTAACAGAGCTCTGTGCTAGCAGCCTACC	1099
	N G V V A P V G Q I N R A L V L A A Y H	367
mtVP7/VP2-150	TGAATGGTGTGCGGCCAGTAGGCCAGATTAACAGAGCTCTGTGCTAGCAGCCTACC	1543
	N G V V A P V G Q I N R A L V L A A Y H	515
	*****	*****
mt144/177/200	ACTAGTGGCTGCGGTGTTGCACGGTCACCGCTTCATTAGTGTGCGTCGGTCTTATGC	1104
	Stop	
mtVP7/VP2-150	ACTAGTGGCTGCGGTGTTGCACGGTCACCGCTTCATTAGTGTGCGTCGGTCTTATGA	1548
	Stop	
	*****	*****

Appendix C-3. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144/177-200/200.

mt144/177/200	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
mtVP7/VP2-200	GTTTAAATCGGTTAGGATGGACCGATAAGCAGCAAGAGCCTGTCCGTTGTACGGGCAT	43
	M D A I A A R A L S V V R A C	15

mt144/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
mtVP7/VP2-200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35

mt144/177/200	TTGCAATCAAATGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
mtVP7/VP2-200	TTGCAATCAAATGGTATAATGGTTAACAAATCATCGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55

mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
mtVP7/VP2-200	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75

mt144/177/200	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
mtVP7/VP2-200	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95

mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
mtVP7/VP2-200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115

mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCACGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135



mtVP7/VP2-200	AGATGCAAACATTGGACCAAGCAAAGTGCACAAACGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135

mt144/177/200	TGCAACAATCTGGCAGATATTACGTACCGCCGGGAATTCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155
mtVP7/VP2-200	TGCAACAATCTGGCAGATATTACGTACCGCCGGGAATTCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155

mt144/177/200	GTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTATGGATGCAGGTGCTGCGGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175
mtVP7/VP2-200	GTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTATGGATGCAGGTGCTGCGGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175

mt144/177/200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAGGCCT-----	561
	V N A L L A P R L Q R P	187
mtVP7/VP2-200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAAGCTGAGATTGGAATGATGTACCCAC	583
	V N A L L A P R L Q K L R F G M M Y P H	195

mt144/177/200	-----:	561
		187
mtVP7/VP2-200	ACTATTATGTTTGATAGTGATTACTGTATTGTACCAAATAAGGGGGAACTAGTATTG	643
	Y Y V L H S D Y C I V P N K G G T S I G	215

mt144/177/200	-----	561
		187
mtVP7/VP2-200	GATCATGGCATATAAGAAAACGTACTGAGGGTATGCAGAAAGCTCTGCTATGTATTCTG	703
	S W H I R K R T E G D A K A S A M Y S G	235

mt144/177/200	-----	561
		187
mtVP7/VP2-200	GAAAAGGTCCACTGAATGACTTACGAGTTAAATTGAGCGGGATGATTATCTCGAGAGA	763
	K G P L N D L R V K I E R D D L S R E T	255
mt144/177/200	-----	561
		187



mtVP7/VP2-200	CAATTATTCAGATCATTGAGTACGGTAAGAAATTAAATTCACTCAGCAGGTGATAAGCAGG	823
	I I Q I I E Y G K K F N S S A G D K Q G	275
mt144/177/200	-----	561
		187
mtVP7/VP2-200	GGAACATTCATTGAAAAATTGGTAGAGTATTGTGATTTTGACAACATCGTTCATG	883
	N I S I E K L V E Y C D F L T T F V H A	295
mt144/177/200	-----	561
		187
mtVP7/VP2-200	CGAAGAAGAAAGAAGAGGGTGAGGATGATACTGCTCGACAGGAGATAAGAAAAGCATGGG	943
	K K K E E G E D D T A R Q E I R K A W V	315
mt144/177/200	-----	561
		187
mtVP7/VP2-200	TTAAGGGGATGCCTTATATGGATTCCTCAAAACCGATGAAAATCACCGTGGATTCAACA	1003
	K G M P Y M D F S K P M K I T R G F N R	335
mt144/177/200	-----	561
		187
mtVP7/VP2-200	GAAATATGCTTTCTGCAGCGCTCGATTCAATTGAGAAAGAGGAACGGTAGATGTTG	1063
	N M L F L A A L D S F R K R N G V D V D	355
mt144/177/200	-----	561
		187
mtVP7/VP2-200	ATCCGAATAAGGGTAAGTGGAAAGAACATATAAAGGAGGTAAACGAAAAATTGAAGAAAG	1123
	P N K G K W K E H I K E V T E K L K K A	375
mt144/177/200	-----	589
	A R R G D A V M I Y	197
mtVP7/VP2-200	CGCAAACCGAAAATGGAGGACAACCATGCCAAGCGCGAGGGGGACGCAGTCATGATCT	1183
	Q T E N G G Q P C Q A R R G D A V M I Y	395

mt144/177/200	ATTCGTTGGAGACCGTTGCGTATATTGTGATCCTCAAGGTGCGAAGCTTCTAGAG	649
	F V W R P L R I F C D P Q G A K L S R V	217



mtVP7/VP2-200	ATTCGTTGGAGACCGTTCGTATTTGTGATCCTCAAGGTGCG AAGCTTCAGAG 1243	
	F V W R P L R I F C D P Q G A K L S R V 415	
	*****	*****
mt144/177/200	TCGACTCACTTGAGAGCGCTCCAGGAAC TTTGTACCGTTGATGGAGTAAATGTTGCAG 709	
	D S L E S A P G T F V T V D G V N V A A 237	
mtVP7/VP2-200	TCGACTCACTTGAGAGCGCTCCAGGAAC TTTGTACCGTTGATGGAGTAAATGTTGCAG 1303	
	D S L E S A P G T F V T V D G V N V A A 435	
	*****	*****
mt144/177/200	CTGGAGATGTCGTCGCATGGAATACTATTGCACCAGTGAATGTTGAAATCCTGGGCAC 769	
	G D V V A W N T I A P V N V G N P G A R 257	
mtVP7/VP2-200	CTGGAGATGTCGTCGCATGGAATACTATTGCACCAGTGAATGTTGAAATCCTGGGCAC 1363	
	G D V V A W N T I A P V N V G N P G A R 455	
	*****	*****
mt144/177/200	GCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCGCTAGACA 829	
	R S I L Q F E V L W Y T S L D R S L D T 277	
mtVP7/VP2-200	GCAGATCAATTTACAGTTGAAGTGTATGGTATACGTCTGGATAGATCGCTAGACA 1423	
	R S I L Q F E V L W Y T S L D R S L D T 475	
	*****	*****
mt144/177/200	CGGTTCCGGAATTGGCTCCAACGCTCACAAAG A TGTTATGCGTATGTCCTCCCAC TTGGC 889	
	V P E L A P T L T R C Y A Y V S P T W H 297	
mtVP7/VP2-200	CGGTTCCGGAATTGGCTCCAACGCTCACAAAGATGTTATGCGTATGTCCTCCCAC TTGGC 1483	
	V P E L A P T L T R C Y A Y V S P T W H 495	
	*****	*****
mt144/177/200	ACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGCAGCCTATTAATCCGCCGATT 949	
	A L R A V I F Q Q M N M Q P I N P P I F 317	
mtVP7/VP2-200	ACGCATTACGCGCTGTCATTTTCAGCAGATGAATATGCAGCCTATTAATCCGCCGATT 1543	
	A L R A V I F Q Q M N M Q P I N P P I F 515	
	*****	*****
mt144/177/200	TTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATG 1009	
	P P T E R N E I V A Y L L V A S L A D V 337	
mtVP7/VP2-200	TTCCACCGACTGAAAGGAATGAAATTGTTGCGTATCTATTAGTAGCTTCTTAGCTGATG 1603	
	P P T E R N E I V A Y L L V A S L A D V 535	
	*****	*****
mt144/177/200	TGTATGCGGCTTGAGACCA GATTT CAGAATGAATGGTGTGCGGCCAGTAGGCCAGA 1069	
	Y A A L R P D F R M N G V V A P V G Q I 357	
	*****	*****



mtVP7/VP2-200 TGTATCGGGCTTGAGACCAGATTTCAGAATGAATGGTGTTGCGGCCAGTAGGCCAGA 1663
Y A A L R P D F R M N G V V A P V G Q I 555

mt144/177/200 TTAACAGAGCTCTTGTGCTAGCAGCCTACCACTAGTGGCTGCGGTGTTGCACGGTCACCG 1104
N R A L V L A A Y H Stop 367

mtVP7/VP2-200 TTAACAGAGCTCTTGTGCTAGCAGCCTACCACTAGTGGCTGCGGTGTTGCACGGTCACCG 1698
N R A L V L A A Y H Stop 565

Appendix C-4. CLUSTAL X Nucleotide and amino acid sequence alignment of VP7mt144/177/200 with VP7mt144/177-250/200.

mt144/177/200	GT T AAATT C GGTTAGGATGGACCGATA G CAGCAAGAGCCTTGTCCGTTACGGGCAT	43
	M D A I A A R A L S V V R A C	15
mtVP7/VP2-250	GT T AAATT C GGTTAGGATGGACCGATA G CAGCAAGAGCCTTGTCCGTTACGGGCAT	43
	M D A I A A R A L S V V R A C	15

mt144/177/200	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35
mtVP7/VP2-250	GTGTCACAGTGACAGATGCGAGAGTTAGTTGGATCCAGGAGTGATGGAGACGTTAGGGA	103
	V T V T D A R V S L D P G V M E T L G I	35

mt144/177/200	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55
mtVP7/VP2-250	TTGCAATCAATAGGTATAATGGTTAACAAATCATTGGTATCGATGAGGCCACAAACCC	163
	A I N R Y N G L T N H S V S M R P Q T Q	55

mt144/177/200	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75
mtVP7/VP2-250	AAGCAGAACGAAATGAAATGTTTTATGTGTACTGATATGGTTTAGCGGGCGCTGAACG	223
	A E R N E M F F M C T D M V L A A L N V	75

mt144/177/200	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95
mtVP7/VP2-250	TCCAAATTGGGAATATTCACCAGATTATGATCAAGCGTTGGCAACTGTGGGAGCTCTCG	283
	Q I G N I S P D Y D Q A L A T V G A L A	95

mt144/177/200	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115
mtVP7/VP2-250	CAACGACTGAAATTCCATATAATGTTCAGGCCATGAATGACATCGTTAGAATAACGGGTC	343
	T T E I P Y N V Q A M N D I V R I T G Q	115

mt144/177/200	AGATGCAAACATTGGACCAAGCAAAGTGCAAACGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135

mtVP7/VP2-250	AGATGCAAACATTGGACCAAGCAAAGTGCACCGGGCCTTATGCAGGAGCGGTTGAGG	403
	M Q T F G P S K V Q T G P Y A G A V E V	135

mt144/177/200	TGCAACAACTGGCAGATATTACGTACCGCCCGGGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155
mtVP7/VP2-250	TGCAACAACTGGCAGATATTACGTACCGCCCGGGGAATTCCCTCGAGCAAGGTCGAACGC	463
	Q Q S G R Y Y V P P G E F L E Q G R T R	155

mt144/177/200	GTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTGTATGGATGCAGGTGCTGCAGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175
mtVP7/VP2-250	GTGGTGGGTACATCAATTCAAATATTGCAGAAGTGTGTATGGATGCAGGTGCTGCAGGAC	523
	G G Y I N S N I A E V C M D A G A A G Q	175

mt144/177/200	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGAGGCCT-----	561
	V N A L L A P R L Q R P	187
mtVP7/VP2-250	AGGTCAATGCGCTGCTAGCCCCAAGGCTGCAGGAGAGTAAGAGAAAAGCAATCCTTGATC	583
	V N A L L A P R L Q E S K R K A I L D Q	195

mt144/177/200	----- · -----	561
		187
mtVP7/VP2-250	AGAATAAGATGTCTAAGGTTAACATGGAGAGATGCGGTTAATGAAAGGATTGTGAGTA	643
	N K M S K V E Q W R D A V N E R I V S I	215

mt144/177/200	----- -----	561
		187
mtVP7/VP2-250	TCGAACCAAAGCGAGGTGAGTGCTATGATCACGGAACCGACATTATCTACCAATTCAA	703
	E P K R G E C Y D H G T D I I Y Q F I K	235

mt144/177/200	----- -----	561
		187
mtVP7/VP2-250	AAAAGCTGAGATTGGAATGATGTACCCACACTATTATGTTTGCATAGTGATTACTGTA	763
	K L R F G M M Y P H Y Y V L H S D Y C I	255
mt144/177/200	----- -----	561
		187

mtVP7/VP2-250	TTGTACCAAATAAGGGGGAACTAGTATTGGATCATGGCATATAAGAAAACGTACTGAGG	823
	V P N K G G T S I G S W H I R K R T E G	275
mt144/177/200	-----	561
		187
mtVP7/VP2-250	GTGATGCGAAAGCTCTGCTATGTATTCTGAAAAGGTCCACTGAATGACTTACGAGTTA	883
	D A K A S A M Y S G K G P L N D L R V K	295
mt144/177/200	-----	561
		187
mtVP7/VP2-250	AAATTGAGCGGGATGATTATCTCGAGAGACAATTATTCAATTGAGTACGGTAAGA	943
	I E R D D L S R E T I I Q I I E Y G K K	315
mt144/177/200	-----	561
		187
mtVP7/VP2-250	AATTTAACATCAGCAGGTGATAAGCAGGGAACATTCAATTGAAAAATTGGTAGAGT	1003
	F N S S A G D K Q G N I S I E K L V E Y	335
mt144/177/200	-----	561
		187
mtVP7/VP2-250	ATTGTGATTTTTGACAACATTGTTATGCGAAGAAGAAAGAGGGTGAGGATGATA	1063
	C D F L T T F V H A K K K E E G E D D T	355
mt144/177/200	-----	561
		187
mtVP7/VP2-250	CTGCTCGACAGGAGATAAGAAAAGCATGGTTAAGGGATGCCTTATGGATTCTCAA	1123
	A R Q E I R K A W V K G M P Y M D F S K	375
mt144/177/200	-----	561
		187
mtVP7/VP2-250	AACCGATGAAAATCACCGGTGGATTCAACAGAAATATGCTTTCTGCAGCGCTCGATT	1183
	P M K I T R G F N R N M L F L A A L D S	395
mt144/177/200	-----	561
		187

mtVP7/VP2-250	CATTCAGAAAGAGGAACGGTGTAGATGTTGATCCGATAAGGGTAAGTGGAAAGAACATA	1243
	F R K R N G V D V D P N K G K W K E H I	415
mt144/177/200	-----	561
		187
mtVP7/VP2-250	TAAAGGAGGTAAACGAAAAATTGAAGAAAGCGCAACCGAAAATGGAGGACAACCATGCC	1303
	K E V T E K L K K A Q T E N G G Q P C Q	435
mt144/177/200	--GCGCGCAGGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTT	619
	A R R G D A V M I Y F V W R P L R I F C	207
mtVP7/VP2-250	AAGCGCGCAGGGGGGACGCAGTCATGATCTATTCGTTGGAGACCGTTGCGTATATTT	1363
	A R R G D A V M I Y F V W R P L R I F C	455

mt144/177/200	GTGATCCTCAAGGTGCGAAGCTTCTAGAGTCGACTCAC TTGAGAGCGCTCCAGGAAC TT	679
	D P Q G A K L S R V D S L E S A P G T F	227
mtVP7/VP2-250	GTGATCCTCAAGGTGCGAAGCTTCTAGAGTCGACTCAC TTGAGAGCGCTCCAGGAAC TT	1423
	D P Q G A K L S R V D S L E S A P G T F	475

mt144/177/200	TTGTCACCGTTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGATGGAATACTATTG	739
	V T V D G V N V A A G D V V A W N T I A	247
mtVP7/VP2-250	TTGTCACCGTTGATGGAGTAAATGTTGCAGCTGGAGATGTCGTCGATGGAATACTATTG	1483
	V T V D G V N V A A G D V V A W N T I A	495

mt144/177/200	CACCA GTGAATGTTGGAAATCCTGGGGCACGCAGATCAATTTACAGTTGAAGTGT TAT	799
	P V N V G N P G A R R S I L Q F E V L W	267
mtVP7/VP2-250	CACCA GTGAATGTTGGAAATCCTGGGGCACGCAGATCAATTTACAGTTGAAGTGT TAT	1543
	P V N V G N P G A R R S I L Q F E V L W	515

mt144/177/200	GGTATACGTCCTTGGATAGATCGTAGACACGGTCCGAATTGGCTCCAACGCTCACAA	859
	Y T S L D R S L D T V P E L A P T L T R	287
mtVP7/VP2-250	GGTATACGTCCTTGGATAGATCGTAGACACGGTCCGAATTGGCTCCAACGCTCACAA	1603
	Y T S L D R S L D T V P E L A P T L T R	535

mt144/177/200	GATGTTATGCGTATGTCCTCCCAC TTGGCACGCATTACGCGCTGTCA TTTTCAGCAGA	919
	C Y A Y V S P T W H A L R A V I F Q Q M	307

mtVP7/VP2-250	GATGTTATGCGTATGTCTCTCCACTGGCACGCATTACGCGCTGTCACTTCAGCAGA	1663
	C Y A Y V S P T W H A L R A V I F Q Q M	555

mt144/177/200	TGAATATGCAGCCTATTAATCCGCCGATTTTCCACCGACTGAAAGGAATGAAATTGTTG	979
	N M Q P I N P P I F P P T E R N E I V A	327
mtVP7/VP2-250	TGAATATGCAGCCTATTAATCCGCCGATTTTCCACCGACTGAAAGGAATGAAATTGTTG	1723
	N M Q P I N P P I F P P T E R N E I V A	575

mt144/177/200	CGTATCTATTAGTAGCTTCTTAGCTGATGTATGCGGCTTGAGACCAGATTCAGAA	1039
	Y L L V A S L A D V Y A A L R P D F R M	347
mtVP7/VP2-250	CGTATCTATTAGTAGCTTCTTAGCTGATGTATGCGGCTTGAGACCAGATTCAGAA	1783
	Y L L V A S L A D V Y A A L R P D F R M	595

mt144/177/200	TGAATGGTGTGCGGCCAGTAGGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACC	1099
	N G V V A P V G Q I N R A L V L A A Y H	367
mtVP7/VP2-250	TGAATGGTGTGCGGCCAGTAGGCCAGATTAACAGAGCTTGTGCTAGCAGCCTACC	1843
	N G V V A P V G Q I N R A L V L A A Y H	615

mt144/177/200	ACTAGTGGCTGCGGTGTTGCACGGTCACCGCTTCATTAGTGTGCGTCGGTTCTTATGC	1104
	Stop	
mtVP7/VP2-250	ACTAGTGGCTGCGGTGTTGCACGGTCACCGCTTCATTAGTGTGCGTCGGTTCTTATGA	1845
	Stop	
